美國商業資訊

2024-12-02 12:56

GE HealthCare to Acquire Remaining 50% Stake in Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan, from Sumitomo Chemical

GE HealthCare to acquire 50% stake from Sumitomo Chemical to assume full ownership of NMP, subject to regulatory approvals
As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, will enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease
Acquisition positions NMP to become partner of choice for global innovators looking to bring novel radiopharmaceuticals to Japan and other Asian markets
Transaction bolsters GE HealthCare’s Pharmaceutical Diagnostics segment and demonstrates its commitment to shaping the future of Molecular Imaging

CHALFONT ST GILES, England--()--GE HealthCare (Nasdaq: GEHC) has agreed to acquire full ownership of Nihon Medi-Physics Co., Ltd (NMP), by purchasing from Sumitomo Chemical (TYO: 4005) the 50% stake it does not already own. As part of GE HealthCare, NMP can build on its expertise developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease. Sumitomo and GE HealthCare expect the agreement to close in early 2025, subject to regulatory approvals.

NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable clinical images across neurology, cardiology and oncology procedures, such as its amyloid visualization radiotracer, VIZAMYL® Injection (Flutemetamol (18F) Injection), used in the Alzheimer’s pathway; DaTSCAN® Injection (Ioflupane (¹²³I) injection) used to evaluate patients with suspected Parkinson’s Disease or Dementia with Lewy Bodies; and MYOVIEW® (Technetium (99mTc) Tetrofosmin), used in SPECT myocardial perfusion imaging for the evaluation of known or suspected coronary artery disease. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. In addition to 13 manufacturing facilities, NMP also focuses on research and development, including nonclinical and clinical development of radiotracers and theranostics research. GE HealthCare has held its 50% stake in NMP since acquiring Amersham plc in 2004 and holds three positions on its Board of Directors.

Kevin O’Neill, President & CEO of the Pharmaceutical Diagnostics (PDx) segment of GE HealthCare, said: “As the third largest pharmaceutical market in the world1, and amongst the leading countries by number of cyclotrons2, Japan is on a path to becoming a leader in the $7 billion molecular imaging global market and a center of excellence for Asian markets. NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring novel products to the Japan market and beyond. This will strengthen our precision care strategy in Asia and our existing footprint in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country.”

Hiroshi Ueda, Executive Vise President, Sumitomo Chemical, said: “We are proud of our 50-year relationship with NMP and our partnership with GE HealthCare to ensure patients in Japan could benefit from access to molecular imaging. At a time of exciting developments in the industry, following its discussions with Sumitomo Chemical, we believe GE HealthCare is the best owner to enable NMP to continue its successful growth journey. I would like to recognize NMP’s leadership and talented team for their significant achievements to date and their commitment to patients.”

As a leading global medical technology and pharmaceutical diagnostics innovator, GE HealthCare provides both molecular imaging equipment and proprietary radiotracers used across major patient care areas. The recent U.S. FDA approval of GE HealthCare’s first-of-its-kind PET radiopharmaceutical, Flyrcado™ (flurpiridaz F 18 injection), its in-licensing of Phase II FAPI assets and broadening theranostics offerings are all examples of the company’s commitment to novel diagnostics that are shaping the future of molecular imaging to drive improved patient outcomes. GE HealthCare’s PDx segment is a global leader in imaging agents used to support over 120 million patient procedures per year globally, equivalent to four patient procedures every second.

The Company expects this transaction to be neutral to Adjusted EPS3,4 in year one and accretive thereafter.

GE HealthCare was advised by Solomon Partners Securities, LLC.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedInXFacebookInstagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals, accessed on October 29, 2024
https://nucleus.iaea.org/sites/accelerators/Pages/Cyclotron.aspx, accessed on October 29, 2024
3 See our latest earnings release dated October 30, 2024 for the definition of Adjusted EPS.
4 Non-GAAP financial measure

Contacts

GE HealthCare Media Contact:
David Morris
M +44 7920 591370
david.j.morris@gehealthcare.com

Mathilde Bouscaillou
M +33 647 008271
mathilde.bouscaillou@gehealthcare.com

Nihon Medi-Physics headquarters and woman looking at molecular imaging images (Photo: Business Wire)

【你點睇?】特朗普指不排除使用武力奪取格陵蘭及巴拿馬運河,你認為言論會否加劇美國與盟友間的不信任?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
4
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
5
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
6
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
7
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
8
回顧展望-新股復燃 | 政策市激發IPO 惟六成新股破發損行情
9
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
10
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
11
回顧展望-共渡時艱 | 表列機構對今明年本港經濟增長預測
12
回顧展望-樓盡六壬 | 甲廈租金明年料跌9%,華潤頻買民生商場
13
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
14
【FOCUS】「無厘頭」減息釀驚嚇,長債失控顯聯儲失信譽
15
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
16
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
17
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
18
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
19
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
20
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
21
神州經脈 | PMI遜預期,滬指全年止跌回升,人幣年度貶幅擴
22
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
23
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
24
回顧展望-息息相關 | 銀行股明年看好滙控,重組有利減低支出
25
高息定存 | 一周高息合集,銀行年尾搶資金,大眾3個月3.6厘
26
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
27
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
28
回顧展望-人幣走貶 | 關稅殺到,先貶為敬,人幣明年勢見7.5
29
【FOCUS】華府停擺鬧劇又起,馬斯克功力再進化
30
港股 | 蕭猷華:恒指維持19700點至21000點上落
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet 賞你】賞 MOKO x Cheeky Cheeky「厚」有福氣利是封 及「熊 MEOW 」火柴盒造型年曆卡!

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老